Colorectal cancer: The challenge

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 5, 1996, Pages

  Bleiberg, H ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

5 fluorouracil; chemotherapy; colorectal cancer; leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NEW DRUG; OXALIPLATIN; RALTITREXED;

ADJUVANT THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

EID: 0029856533     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00319-X     Document Type: Conference Paper

References (58)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995, 45, 8-30.
2. National Institute of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264, 1444-1450.
3. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Cancer 1994, 331, 1669-1674.
4. Goldbohm RA, van den Brandt PA, van't Veer P, et al. Cholecystectomy and colorectal cancer; evidence from a cohort study on diet and cancer. Int J Cancer 1993, 53, 735-739.
5. Giovannucci E, Rimm EB, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US men. J Natl Cancer Inst 1994, 86, 183-191.
6. Willett W. The search for the causes of breast and colon cancer. Nature 1989, 388, 389-394.
7. Mayer RJ, O'Connell MJ, Tepper JE, Wolmark N. Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 1989, 81, 1359-1364.
8. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122, 321-326.
9. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993, 306, 752-755.
10. Glimelius B, Pahlman L, Graf W, Adami HO. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992, 10, 904-911.
11. Carter SK. Large bowel cancer: the current status of treatment. J Natl Cancer Inst 1976, 56, 3-10.
12. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, and leucovorin. A randomised trial of the Northern California Oncology Group. J Clin Oncol 1989, 7, 1427-1436.
13. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal cancer: a prospective randomised phase III trial. J Clin Oncol 1989, 7, 1419-1426.
14. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987, 14 (Suppl 4), 3-11.
15. MacMillan WE, Wobery WH, Welling PC. Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 1978, 38, 3479-3482.
16. Weh HJ, Wilke J, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994, 5, 233-237.
17. Diaz-Rubio E, Aranda E, Camps C, et al. A phase II study of weekly 48-hour infusions with high dose fluorouracil in advanced colorectal cancer: an alternative to biochemical modulation. J Infusional Chemotherapy 1994, 4, 58-61.
18. Bleiberg H, Vanderlinden B, Buyse M, et al. Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU) and allopurinol (HHP) versus 5-fluorouracil in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study. Cancer Invest 1990, 8, 469-473.
19. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989, 7, 425-432.
20. Lokich J, Ahlgren J, Cantrell JE, et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinomas: a Mid-Atlantic Oncology Program study. Cancer 1991, 67, 14-19.
21. Hansen R, Ryan L, Anderson T, et al. A phase III trial of bolus 5FU versus protracted infusion of 5FU ± cisplatin in metastatic colorectal cancer: an Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 1990, 9, 124 (abstr).
22. Kemeny N, Daly J, Reichman MA, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987, 107, 459-465.
23. Hohn DC, Stagg RJ, Friedman MA, et al. A randomised trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver. The Northern California Oncology Group trial. J Clin Oncol 1989, 7, 1646-1654.
24. Chang AE, Schneider PD, Sugarbaker PH. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206, 685-693.
25. Martin JK, O'Connell MJ, Wieand HS, et al. Intraarterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990, 125, 1022-1027.
26. Rougier PH, Hay JM, Oliver JM, et al. A controlled multicentre trial of intrahepatic chemotherapy (IHC) vs standard palliative treatment for colorectal liver metastases. Proc Am Soc Clin Oncol 1990, 9, 104 (abstr).
27. Kemeny N, Seiter K, Conti J, et al. Hepatic arterial FUDR and leucovorin in previously untreated patients with unresectable liver metastases from colorectal carcinoma. Cancer 1994, 73, 1134-1142.
28. Meta-analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88, 252-258.
29. Labianca R, Pancera G, Cessana B, et al. Cisplatin and 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur J Cancer Clin Oncol 1988, 24, 1579-1581.
30. Loehrer PJ, Turner S, Kubilis P, et al. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group Trial. J Clin Oncol 1988, 6, 642-648.
31. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1418.
32. O'Connell MJ, Martensen JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331, 502-507.
33. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomised trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5, 1559-1565.
34. Martoni A, Cricca A, Guaraldi M, Farris A, Pannuti F. A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report. J Chemother 1989, 1, 197-202.
35. Leichman CG, Fleming TR, Muggia FM, et al. Phase I study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995, 13, 1303-1311.
36. Erlichman C, Fine S, Wong A, Elhakim T. A randomised trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988, 6, 469-475.
37. Nobile MT, Rosso R, Sertoli MR, et al. Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992, 28A, 1823-1827.
38. Labianca R, Pancera G, Aitini E, et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of "GISCAD® (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991, 2, 673-679.
39. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomised comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990, 8, 491-501.
40. Steinke B, Giunther E, Hirschman WD, et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer -preliminary results of a randomised trial. Semin Oncol 1992, 19, 141-147.
41. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Folinic acid does improve 5-fluorouracil activity in vivo: results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 1993, 5, 52-55.
42. Di Constanze F, Bartolucci R, Calabresi F, et al. Fluorouracil alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992, 3, 371-376.
43. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
44. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and folinic acid in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
45. Blijham G, Wagener Th, Wils J, et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 1996, 14, 2266-2273.
46. Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
47. Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alpha-1a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990, 8, 2027-2031.
48. Kemeny N, Younes A, Seiter K, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 1990, 66, 2470-2475.
49. Moertel CG, Flemming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Eng J Med 1990, 232, 352-358.
50. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 1993, 11, 1879-1887.
51. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
52. Glimelius B, Hoffman K, Graf W, et al. Cost effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995, 6, 267-274.
53. Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994, 73, 556-562.
54. Hansen RM, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion. A review of current progress. Oncology 1989, 46, 245-250.
55. Macdonald JS on behalf of the International Working Group in Colorectal Cancer. A study of the treatment and management of advanced colorectal cancer: the colorectal care pathway review. Proceedings ASCO 1996, 15, 230.
56. Sainsbury R, Howard B, Rider L, et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995, 345, 1265-1270.
57. Kemeny N, Lokich JJ, Anderson N, Ahlgren JD. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993, 71, 9-18.
58. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. Br Med J 1990, 300, 1459-1460.